Saltar al contenido
Merck

DDX5 promotes oncogene C3 and FABP1 expressions and drives intestinal inflammation and tumorigenesis.

Life science alliance (2020-08-21)
Nazia Abbasi, Tianyun Long, Yuxin Li, Brian A Yee, Benjamin S Cho, Juan E Hernandez, Evelyn Ma, Parth R Patel, Debashis Sahoo, Ibrahim M Sayed, Nissi Varki, Soumita Das, Pradipta Ghosh, Gene W Yeo, Wendy Jia Men Huang
RESUMEN

Tumorigenesis in different segments of the intestinal tract involves tissue-specific oncogenic drivers. In the colon, complement component 3 (C3) activation is a major contributor to inflammation and malignancies. By contrast, tumorigenesis in the small intestine involves fatty acid-binding protein 1 (FABP1). However, little is known of the upstream mechanisms driving their expressions in different segments of the intestinal tract. Here, we report that the RNA-binding protein DDX5 binds to the mRNA transcripts of C3 and Fabp1 to augment their expressions posttranscriptionally. Knocking out DDX5 in epithelial cells protected mice from intestinal tumorigenesis and dextran sodium sulfate (DSS)-induced colitis. Identification of DDX5 as a common upstream regulator of tissue-specific oncogenic molecules provides an excellent therapeutic target for intestinal diseases.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Flavopiridol hydrochloride, ≥98% (HPLC), powder
Sigma-Aldrich
MISSION® esiRNA, targeting human DDX5